Task Bisphosphonates as a Countermeasure to Space Flight Induced Bone Loss: SMO-021 (Completed)
Last Published:  07/30/20 02:45:15 PM (Central)
Short Title: Bisphosphonates SMO
Responsible HRP Element: Human Health Countermeasures
Collaborating Org(s):
Research Operations and Integration (ROI)
Funding Status: Completed - Task completed and produced a deliverable
Procurement Mechanism(s):
Directed
Aims:
  1. Obtain preflight and postflight Quantitative Computed Tomography (QCT) scans of the hip. The QCT scans will provide volumetric bone density information of both cortical and trabecular (spongy) bone regions of the hip. This study aims to show that bisphosphonates will significantly reduce bone mineral density loss and the increased risk of renal stone formation documented previously on untreated ISS crewmembers.
  2. Perform: preflight and postflight Dual-energy X-Ray Absorptiometry (DXA) scans of the whole body, spine, hip, and heel; preflight and postflight scans of the tibia using peripheral Quantitative Computed Tomography (pQCT); preflight and postflight abdominal/retroperitoneal Ultrasound scans; preflight and postflight blood draws to measure serum markers of bone metabolism, and preflight, in-flight, and postflight urine collections to measure urinary markers of bone metabolism. Urine measurements will also be used to look at the risk for developing renal stones before, during and after flight.

Integration/Unique Aspects: The decalcification of bone during skeletal adaptation to spaceflight is a major contributing risk factor for renal stone formation.

Mappings